Sputum proteomics in lung disorders.
Asthma
Biomarker
COVID-19
Chronic obstructive pulmonary disease
Cystic fibrosis
Lung cancer
Mass spectrometry
Proteomics
Sputum
Tuberculosis
Journal
Advances in clinical chemistry
ISSN: 2162-9471
Titre abrégé: Adv Clin Chem
Pays: United States
ID NLM: 2985173R
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
7
8
2024
Statut:
ppublish
Résumé
Lung diseases affect pulmonary and respiratory function and are caused by bacterial viral and fungal infection as well as environmental factors. Unfortunately, symptom overlap between various pulmonary diseases often prevents clear differentiation and uncertain diagnosis. Accordingly, identification of specific markers of inflammatory activity in early disease stage could potential unveil the intrinsic molecular mechanisms of the underlying pathology. Proteomic studies aimed at understanding the genetic/environmental contributions to the development and progression of lung diseases represent a promising approach for diagnosis and treatment. The fluid phase of sputum represents a rich protein source and is frequently used in these studies. This chapter addresses causes of lung disorders, sputum composition, collection and processing as well as the clinical significance and challenges associated with the presence of interfering factors. Basics of proteomics and mass spectrometry are also described, together with the analytical approaches to investigate the sputum proteome. Finally, we explore the application of sputum proteomics in severe lung disorders including COVID-19 infection, chronic obstructive pulmonary disease, asthma, cystic fibrosis, lung cancer and tuberculosis.
Identifiants
pubmed: 39111963
pii: S0065-2423(24)00093-3
doi: 10.1016/bs.acc.2024.06.002
pii:
doi:
Substances chimiques
Biomarkers
0
Proteome
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-208Informations de copyright
Copyright © 2024. Published by Elsevier Inc.